Acknowledgements
P., UC
HAAS
We thank the trial participants, their families and our fellow investigators involved in this trial: B. Suter (Texas Children’s Hospital, Houston, Texas, US), C. Buhrfiend, P. Heydemann (Rush University Children’s Hospital, Chicago, Illinois, US), S. Standridge, E. Broomall, K. Peariso (Cincinnati Children’s Hospital Medical Center, Division of Neurology and University of Cincinnati, College of Medicine, Department of Pediatrics, Cincinnati, OH, US), C. Fu, S. Peters (Vanderbilt University Medical Center, Nashville, Tennessee, US), R. Haas, N. Guido-Estrada (University of California, San Diego, La Jolla, California, US), S. Kessler, S. Massey (Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, US), A. Ananth (University of Alabama at Birmingham, Birmingham, Alabama, US), R. Ryther, J. Weisenberg (Washington University School of Medicine, Saint Louis, Missouri, US), D. Lieberman, R. Witt, D. Friedman (Boston Children’s Hospital Harvard Medical School, Boston, Massachusetts, US), A. Stratton (Children’s Hospital Colorado, Aurora, Colorado, US), V. Narayanan, N. Belnap (Translational Genomics Research Institute, Phoenix, Arizona, US), R.J. Hagerman, B. Restrepo, M. Jones* (UC Davis MIND Institute, Sacramento, California, US; *investigator passed away before participating in the trial), S.A. Skinner (Greenwood Genetic Center, Greenwood, South Carolina, US), T. Feyma, A. Beisang (Gillette Children’s Specialty Healthcare, Saint Paul, Minnesota, US), A. Djukic (Montefiore Medical Center, Children’s Hospital at Montefiore, Bronx, New York, US), Y. Shiloh-Malawsky, D. Cejas, Z. Fan (the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US), R. Saneto (Seattle Children’s, Seattle, Washington, US), J. Ranells, A. Sanchez-Valle, C. Griffith, K. Morgan (University of South Florida Children’s Medical Services, Tampa, Florida, US), C. Smith-Hicks, M. Jain (Kennedy Krieger Institute, Clinical Trials Unit, Baltimore, Maryland, US), S. Parikh, G. Hsich (Cleveland Clinic, Cleveland, Ohio, US), A.L. Talboy, R. Sanchez (Emory Genetics Clinical Trial Center, Atlanta, Georgia, US). We also thank K. Raudibaugh, K. O’Rourke-Kosko, C. Murphy and R. Nunez of Acadia Pharmaceuticals. The study was funded by Acadia Pharmaceuticals. The study sponsor (Acadia Pharmaceuticals) contributed to the study design, the writing of the report and the decision to submit the article for publication. Medical writing support was provided by S. Murray, MSc, CMPP, of Evidence Scientific Solutions and funded by Acadia Pharmaceuticals.